Oleg Gluz

Oleg Gluz contributes to the West German Study Group and has been involved in WSG ADAPT trials pioneering response-guided adaptive neoadjuvant strategies in early breast cancer, integrating early response assessment with treatment adaptation. His work on the EXTENET trial and post-neoadjuvant HER2+ management has informed extended adjuvant neratinib use. He contributes to de-escalation approaches in HER2-low and HER2+ early breast cancer based on neoadjuvant response patterns. Gluz presents at international breast cancer symposia and has contributed to AGO breast cancer guidelines.